Drug intelligence / Profile preview

artemisia annua

Development stage: Phase 2
Lead developer: Sanofi
Modality: Small Molecules
Administration: Sublingual

Overview

Artemisia annua, also known as sweet wormwood or annual wormwood, is a plant that is being investigated for its therapeutic potential. It has shown a promising role in the treatment of ulcerative colitis, where its mechanisms of action are being elucidated, particularly concerning its effects on inflammation and intestinal epithelial barrier injury. Additionally, Artemisia annua is being developed for sublingual immunotherapy to treat allergic rhinitis and allergic rhinoconjunctivitis.

Other names: 黄花蒿Artemisia annua L.

Targets

JAK2 (Janus kinase 2)CYP3A4 (Cytochrome P450 3A4)Mpro (3C-like proteinase of SARS-CoV-2)CYP2B6 (Cytochrome P450 2B6)

Beyond the preview

Go deeper on artemisia annua.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemisia annua.

Explore the full profile